Post on 27-Dec-2015
Challenges and opportunities in New Zealand’s pharmaceutical sceneKevin Sheehy – Chief Executive, Medicines New Zealand
Dalton Kelly – Chief Executive, New Zealand Cancer Society
Assoc. Prof. Ken Whyte – University of Auckland Medical School
Medicines Access: Looking aheadKevin Sheehy General ManagerMedicines New Zealand
Opportunities for better health of patients are a challenge for funders
Clinical ResearchIt’s about improving healthcare
How do we sustain this improvement in healthcare?
Opportunities
Personalised medicine
Integrated decision making a complex problem
Medicine pipeline developments
Challenging demographics
Ageing population – degenerative illness
Later retirement
Funding challenges
Medicines Access: Looking ahead
“Genetics plays an important role in most diseases: cancer, obesity, diabetes, cardiovascular, neurologic and psychiatric diseases. All of medicine.” - Professor of Genetics at Harvard Medical School and first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Dr. Raju Kucherlapati
Throat swabs or genetic tests Each have the ability to better target treatment Require integrated decision making (discussion between the budget silos)
Many new treatments are expensive to develop
but
can improve cost effectiveness by treating those who respond best
Personalised medicine
Contributing to New Zealand’s economic prosperity
Savings vs improved health
Include costs not currently considered
Back to work
Cost of disease to society
Compare to other health interventions
Ministry work commencing
Better understand value proposition
Integrated decision making
Over 20 new medicines per year registered by FDA Cancer Immunology Virology Metabolic diseases Neurology
Biologics
Increasing development complexity and costs
New indications
Medicine pipeline developments
OldModel
One chemistOne weekOne molecule
NewModel
One chemistOne computerOne robotOne week10,000 Molecules
Medicine pipeline developments cont
Age related illness
Non Communicable Diseases Heart, brain, metabolic, cancer
Ageing effect dominant reason for increasing cancer
Over 65s increasing by 4000 people per month
Retiring later?
R&D improving treatmentse.g. Biologicals for rheumatoid arthritis
Challenging demographics
Medicine = medical device = Surgery ?
But they are all fruit!Healthcare investments can and should be compared
Funding challenges
Making Named Patient Pharmaceutical Assessment (NPPA) work
Hospital medicines Greater transparency/engagement and responsiveness Measuring performance Understanding unmet needs
Current funding system challenges
Questions?